Characteristics and treatments of large cystic brain metastasis: radiosurgery and stereotactic aspiration. by Kim, Moinay et al.
UCLA
UCLA Previously Published Works
Title
Characteristics and treatments of large cystic brain metastasis: radiosurgery and stereotactic aspiration.
Permalink
https://escholarship.org/uc/item/06x9x3ch
Journal
Brain tumor research and treatment, 3(1)
ISSN
2288-2405
Authors
Kim, Moinay
Cheok, Stephanie
Chung, Lawrance K
et al.
Publication Date
2015-04-29
DOI
10.14791/btrt.2015.3.1.1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1INTRODUCTION
The incidence of brain metastasis in cancer patients is about 
20–40%, with about 170,000 new cases every year in the Unit-
ed States [1,2]. Although common, the clinical manifestations 
have not been well studied. The incidence of brain metastasis 
is increasing due to the improvement of diagnostic screening 
tools and treatments, leading to longer life spans of cancer pa-
tients [3]. Without intervention, brain metastases have a poor 
prognosis, with a median survival of only 1 month [4-6]. Stan-
dard treatments for brain metastasis have not been well estab-
lished in literature, however some general guidelines are avail-
able; surgery, radiosurgery, whole brain radiation therapy (WB- 
RT) and chemotherapy have proved to be effective.
Cystic brain metastases are relatively rare [7] and the patho-
genesis of cyst formation is not clear. According to literature [8] 
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the exudative fluid, often seen as massive edema surrounding 
the metastatic tumor, tends to collect inside the tumor and ex-
pand as a cystic mass depending on its local conditions. Cum-
ings [9] suggested the cyst formation is from the tumor degen-
eration followed by transudation of fluid from nearby blood 
vessels. Alternatively, Gardner et al. [10] advocates that the cys-
tic components in brain tumors are merely interstitial fluid 
without its normal drainage route due to the lack of lymphat-
ics in the surrounding brain.
Large cysts often produce neurologic deficits because of its 
mass effect. Nevertheless, cystic tumors that cause symptoms 
must be evaluated and carefully treated. Single, large cystic 
brain tumors have been traditionally treated through surgery. 
However, radiosurgery has gained increasing prevalence for 
the treatment of brain metastasis [11-18] and possesses many 
advantages over surgical resection. For example, radiosurgery 
can be used to treat multiple metastases and surgically inacces-
sible locations such as eloquent or deep areas. In addition, re-
section is often not a safe choice for patients with severe systemic 
diseases or advanced age as their physical condition may be poor 
and unsuitable for general anesthesia [19,20]. 
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However, cystic metastatic tumors themselves are often large 
and radiosurgery may not be feasible. In this case, the tumors 
are treated with a decreased radiation dosage to avoid radia-
tion-associated complications [21]. Flickinger [22] reported that 
tumors with a cystic component greater than 10 mL did not 
appear to be effectively controlled by radiosurgery alone. There-
fore, it is essential to decrease the volume of the cystic compo-
nents before treating them with radiosurgery. The combina-
tion of cyst aspiration and radiosurgery is one possible method 
[15,23-25] that may be more effective and safer than radiosur-
gery alone.
CHARACTERISTICS
Large cystic brain metastases share common characteristics 
with each other. Ebinu et al. [26] analyzed 111 metastatic le-
sions from 73 patients and reported that lung cancer was the 
primary cancer in 37 patients (51%) and breast cancer in 7 (10%) 
patients. Other authors showed similar results with lung can-
cer reported as the most common origin of brain metastases with 
breast cancer coming in second [19,27,28]. Cystic change is most 
common in lung cancer, but also occurs in other metastatic can-
cers like breast, pancreas, kidney and even melanoma [29]. 
However, there was a conflicting study that reported breast 
cancer (50%) as the most common origin and lung cancer (30%) 
as the second [30]. The distribution of brain metastases varied 
widely. Some papers did not mention the specific anatomical 
location of the tumor, but supratentorial lesions are more com-
mon than infratentorial lesions [19,27]. Ebinu et al. [26] and 
Yamanaka et al. [30] showed that the frontal lobe (39%) was 
the most common site of brain metastases, followed by pari-
etal lobe and cerebellum, but Higuchi et al. [28] reported that 
the parietal lobe (28%) was the most common site. The mean 
age for detecting cystic brain metastasis is in the fifties and 
there is no specific evidence to suggest a preposition for either 
sex [19,21,27,28,30]. Large cystic brain metastases did not ap-
pear to be specific to a particular recursive partitioning analy-
sis (RPA) class but most papers reported class I and II as the 
most common and class III as the least [RPA index: there are 
three classes in descending prognostic expectancy from 1 to 3; 
class 1, for patients with Karnofsky performance status (KPS) 
70, <65 years of age, with controlled primary and no evidence 
of extracranial metastasis; class 3, for patients with KPS <70; 
class 2 for all others] [19,26,27]. Franzin et al. [19] reported a 
mean KPS score of 88 (range 70–110) for patients with cystic 
brain metastases, whereas Yamanaka et al. [30] reported a mean 
KPS score of 70 (range 50–100). Other authors showed simi-
lar results. The volume of cystic metastases, as measured prior 
to radiosurgery, ranged from 3–100 mL with a mean target 
volume of 20–25 mL [19,21,27,28]. 
TREATMENTS
Most hospitals follow similar protocols for treating cystic 
metastases. After administering a local anesthetic agent to the 
head pin sites, a Leksell stereotactic frame is applied using fine 
adjustments. Magnetic resonance images (MRI) are then ob-
tained to localize the tumors. The path for the aspiration nee-
dle is calculated using programs such as the SurgiPlan Electa 
Instruments system (Elekta, Sweden). The patient is then placed 
in an appropriate position to deliver the local anesthetic agent 
and start the stereotactic needle aspiration. The cyst aspiration 
is done with an aseptic technique. After the drainage, a second 
set of MRIs is obtained to calculate the reduction in volume. 
Some hospitals perform the aspiration and the radiosurgery 
on a same day while other hospitals perform the two proce-
dures within 48 hours of each other. The mean prescription 
dose to the tumor margin is 17–21 Gy with a range from 12–25 
Gy [19,21,26-28]. Most hospitals recommend a follow-up MRI 
every 2 to 3 months post-treatment. Patients are usually dis-
charged on the same day of the procedure or within a few days.
RESULTS
Brain tumor size is an essential factor in determining treat-
ment plans. Studies [4,13,14] show that local tumor control rates 
of metastases after radiosurgery ranged from 73–94%. The 
correlation between tumor volumes, prescription dose, and pa-
tient survival rates are well known. Schoeggl et al. [31] report-
ed that brain tumors with a maximum diameter less than 17 
mm had a better outcome. Sneed et al. [32] noted that a small-
er tumor volume was also very closely related to patient sur-
vival. Petrovich et al. [33] concluded that tumor volume is an 
important prognostic factor influencing survival rate by show-
ing that the local tumor control rate one year post-treatment 
was 90% in tumors <3 mL and 78% in larger lesions (11 months 
for tumor volume <1 mL and 6 months for tumor volume >9 mL). 
By reducing tumor volume, cystic aspiration aims to accom-
plish two goals: achieve a better likelihood of tumor control with 
radiosurgery, and increase the radiosurgery dosage as larger tu-
mor volumes limit the single fraction dose. Franzin et al. [19] 
reported that all but one patient showed good reduction of the 
cyst volume after stereotactic drainage. The mean cyst volume 
was reduced from 21.8 mL to 10.1 mL; the volume reduction 
was approximately 50.8% (range 5–72%). In his study of 23 
patients, 2 (8.7%) presented with tumor progression after ra-
diosurgery, 9 (39.1%) presented with remote progression, and 
3 (13%) experienced both. In 5 patients, 7 of the 81 metastases 
progressed after radiosurgery. Higuchi et al. [28] showed sim-
ilar results with a mean tumor volume reduction of 20.3 cc to 
10.3 cc following aspiration. Good tumor control was obtained 
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in 16 of 21 cases that were evaluated with a median follow-up 
of 11 months (range 1–27 months). Park et al. [27] showed bet-
ter results with the mean tumor volume reduced from 23.2 cc 
(range 7.9–100.9 cc) to 4.3 cc (range 0.2–19.0 cc) with a mean 
tumor volume reduction of 77.9% (range 31.4–98.3%) (Fig. 1, 
2). After treatment, 13 patients (54.2%) showed tumor control, 
and 11 (45.8%) showed tumor progression with 5 (20.8%) lo-
cally and 6 (25.0%) remotely. One patient (4.2%) presented with 
remote tumor progression and WBRT was required, whereas 
the other 10 patients (41.7%) needed a second course of radio-
surgery. Radiation Therapy Oncology Group 90-05 protocol 
suggest that tumors with a maximum diameter of 31–40 mm, 
21–30 mm and ≤20 mm should receive the maximum tolerat-
ed doses of 15, 18, and 24 Gy, respectively [34]. In one study, the 
volume before drainage was greater than 14 mL (average di-
ameter >30 mm) in 22 (66%) of 33 lesions, which would have 
given a prescription isodose of <18 Gy. However after drain-
age, the target volume of 15 out of 22 lesions was <10 mL (av-
erage diameter <26 mm) which leads to a prescription isodose 
>18 Gy [19]. 
One great advantage of cyst drainage is acute symptomatic 
relief due to a reduction in mass effect. Liu et al. [21] aspirated 
cystic metastatic tumor from 43 of 77 patients (excluding tu-
mors that were glial, vestibular schwannomas, etc.) and found 
A
B
Fig. 1. Axial and coronal contrast-enhanced T1-weighted magnetic resonance images of the brain of a 66-year-old woman with a large cystic 
brain metastasis, with hemorrhage, that developed from non-small lung cancer. A: Before aspiration the initial cyst volume was 25.5 cc. B: Af-
ter cyst aspiration, cyst volume was 5.5 cc. The prescription dose was 20 Gy and MR shows 6 years after postoperatively.
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that 68 patients (88.3%) showed immediate improvement of 
symptoms following drainage. In the study, 62 patients had a 
follow-up for at least 6 months and 5 patients showed disap-
pearance of the metastatic cystic tumor. Another study [27] which 
treated patients with radiosurgery after stereotactic cyst drain-
age, found that 19 out of 24 patients (79.2%) showed improve-
ment in symptoms related to their brain metastasis. Further-
more, Niranjan et al. [24] reported on the importance of tumor 
location for symptomatic relief. In his study, 11 of 13 patients 
(77%) with cystic tumors in deep locations (brain stem, hypo-
thalamus, and thalamus) noted symptomatic improvement. 
Of the patients with cysts in a lobar location, 17 of 25 (68%) 
experienced improvement following cyst aspiration. Thus, 
these studies support the increase in feasibility and efficacy of 
Gamma Knife Surgery in improving patient outcomes.
Franzin et al. [19] reported a local tumor control rate of 91.3% 
and all cystic tumors except for 2 were controlled at the end of 
follow-up (mean follow-up of 11.3 months, with a median of 9 
months). The median time of tumor progression was 10 months. 
In one study [28], 16 of the 21 patients (76%) had tumors that 
were controlled well at the end of follow-up or at the time of the 
patient’s death from non-neurological causes (median follow-
ing up 11 months). During follow-up, 19 patients died, 1 pa-
tient remained alive, and 5 patients were lost to follow-up. Of 
the 19 patients who died, only 3 patients displayed significant 
neurological progression. Gerosa et al. [14] showed 93% local 
A
B
Fig. 2. Axial and coronal contrast-enhanced T1-weighted magnetic resonance images of the brain of a 73-year-old woman with a large cystic 
brain metastasis, that developed from breast cancer. A: Before aspiration the cyst volume was 43.2 cc. B: After cyst aspiration, cyst volume 
was 18.9 cc. The prescription dose was 18 Gy and MR shows about 10 postoperative months.
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tumor control in 804 patients with brain metastases, 15 of which 
were cystic lesions. Another study [27] revealed that only 1 pa-
tient (4.2%) died from the progression of brain metastasis while 
3 patients (12.5%) died from unrelated illnesses and 6 patients 
(25.0%) died from primary cancer progression (mean follow-
up 13.1 months). Median progression-free survival after treat-
ment was 14.1 months. Other authors reported a median sur-
vival of 7.5 months in 8 patients [25] and 26.6 months in 15 
patients [14] with a 1-year actuarial survival rate of 9%. Reac-
cumulation of cyst contents was observed after the aspiration. 
In a study by Park et al. [27], 12 lesions (48.0%) were treated 
with additional Ommaya reservoir insertion after stereotactic 
drainage. Higuchi et al. [28] had reaccumulation of cyst con-
tents in 2 patients (9%) who required Ommaya reservoir place-
ment as well. Intracystic hemorrhage associated with Omma-
ya reservoir placement was seen in four tumors (16%) in two 
patients [30]. These tumors did not shrink, but no neurologi-
cal deterioration was observed.
Severe acute complications related to the aspiration or ra-
diosurgery are not frequently observed. However, possible 
complications include neurosurgical deficits, hemorrhage, sei-
zures, and infections [35]. The mortality rate in several large 
series has been less than 1% and complication rates vary from 
0% to 7% [35,36]. Approximately one-third of patients expe-
rienced mild transitory symptoms, including headache, nau-
sea, and dizziness following radiosurgery [37]. More severe 
complications such as facial palsy, trigeminal neuropathy, and 
visual symptoms occur 6 to 9 months after the procedure [38]. 
The incidence of radiation necrosis was 6.6% in one study and 
no events of radiation necrosis were found in lesions with vol-
umes less than 15 mL. This suggests that reducing treatment 
volume to less than 15 mL will reduce complications due to ra-
diation included necrosis [19]. However, if the tumor volume 
remains large even after drainage, fractionated radiosurgery 
can be used to mitigate the risk of necrosis by reducing the vol-
ume of normal brain receiving a single, high dose fraction [39]. 
There is also the theoretical risk for tumor cell seeding along 
the aspiration needle tract, but the incidence of such events are 
poorly described in literature. To date, these rare complications 
have only occurred after stereotactic biopsy of pineoblastoma, 
craniopharyngioma, anaplastic astrocytoma, and certain intra-
cranial metastasis [40-43]. 
There are many studies that investigated the prognostic fac-
tors for patient survival and tumor control after radiosurgery. 
In one study [19], the extension of the extracranial illness (p= 
0.001), male sex (p=0.02) and different tumor types (p=0.006) 
were statistically significant prognostic factors. A statistically 
significant correlation between tumor volume and the pre-
scription radiation dose and final tumor control rate was not 
found [19]. Tendulkar et al. [44] concluded lung cancer (p=0.02) 
as the subtype identified as a positive predictor and prior WBRT 
(p=0.03) as a less favorable response to radiosurgery. The most 
important prognostic value was the RPA classification (p<0.001); 
the survival rate of patients included in RPA class I (median 25 
months) was higher than that in RPA class II (median 8 months). 
The importance of RPA classification has been confirmed in 
other studies as well. Lutterbach et al. [45] showed median sur-
vival rates of 13.4, 9.3, and 1.5 months in RPA classes I, II, and 
III, respectively; Sneed et al. [46] found a median survival rate 
of 14 months for patients in RPA class I and 8.2 months for 
patients in RPA class II. Another study [27] also reported an 
overall median survival after radiosurgery of 17.8 months 
(range 1–39 months); 17.8 months for patients in RPA class I, 
10.9 months for patients in RPA class II, and 6.1 months for 
patients in RPA class III. Therefore, RPA classifications can be 
used as a valid tool for predicting prognosis in patients with 
brain metastases. Patients in RPA class III are typically not healthy 
enough to permit general anesthesia for surgery, but the great 
advantage of radiosurgery is that this modality can be per-
formed using only local anesthesia. This reinforces the effica-
cy of radiosurgery after stereotactic cyst aspiration for inacces-
sible cystic lesions on a wide range of patient types [27]. 
CONCLUSION
The aim of this review is to evaluate and assess the use of com-
bining stereotactic drainage in cystic metastases tumors in im-
proving the efficacy and feasibility of radiosurgery. The results 
of the cited studies show great potential in the non-surgical 
management of cystic metastases. There have been no direct, 
randomized clinical comparisons between radiosurgery and 
other surgical-radiation protocols, but it has been shown that 
patients with single lesions can achieve similar or better results 
with radiosurgery when compared to those who were treated 
with other protocols [22,47-50]. Stereotactic radiosurgery is a 
non-invasive and effective treatment tool when measured in 
terms of local tumor control and patient survival rates. Surgery 
and radiosurgery should not be considered as separate treat-
ment techniques, but rather complementary. When radiosur-
gery is not efficient due to the size of the tumor, the aspiration 
of cystic metastases can be considered an option. Aspiration 
allows the radiation dose to be reduced to the target volume, 
thereby decreasing the chance of radiation induced necrosis or 
other complications. Therefore, it is possible to deliver a high-
er prescription dose to the tumor while also promoting acute 
symptoms relief from the decreased mass effect. The available 
literature shows that the combined usage of stereotactic aspira-
tion and radiosurgery has the potential ability to improve pa-
tient outcomes.
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